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Abstract
Background: The question of whether to treat patent ductus arteriosus (PDA) early or wait until symptoms appear
remains high on the research agenda for neonatal medicine. Around 7000 extremely preterm babies under 29
weeks’ gestation are born in the UK every year. In 40% of cases the PDA will fail to close spontaneously, even by 4
months of age. Untreated PDA can be associated with several serious and life-threatening short and long-term
complications. Reliable data to support clinical decisions about PDA treatment are needed to prevent serious
complications in high risk babies, while minimising undue exposure of infants. With the availability of routine
bedside echocardiography, babies with a large PDA can be diagnosed before they become symptomatic.
Methods: This is a multicentre, masked, randomised, placebo-controlled parallel group trial to determine if early-
targeted treatment of a large PDA with parenteral ibuprofen in extremely preterm babies (23+ 0–28+ 6 weeks’
gestation) improves short and long-term health and economic outcomes. With parental informed consent,
extremely preterm babies (born between 23+ 0–28+ 6 weeks’ gestation) admitted to tertiary neonatal units are
screened using echocardiography. Babies with a large PDA on echocardiography, defined by diameter of at least
1.5 mm and unrestricted pulsatile PDA flow pattern, are randomly allocated to either ibuprofen or placebo within
72 h of birth. The primary endpoint is the composite outcome of death by 36 weeks’ postmenstrual age or
moderate or severe bronchopulmonary dysplasia (BPD) at 36 weeks postmenstrual age.
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Discussion: Prophylactic pharmacological treatment of all preterm babies unnecessarily exposes them to
potentially serious side effects of drug treatment, when their PDA may have closed spontaneously. However,
delaying treatment until babies become symptomatic could result in loss of treatment benefit as irreversible
damage may have already been done.
Targeted, early pharmacological treatment of PDA in asymptomatic babies has the potential to overcome the
disadvantages of both prophylactic (overtreatment) and symptomatic approaches (potentially too late). This could
result in improvements in the clinically important short-term clinical (mortality and moderate or severe BPD at 36
weeks’ postmenstrual age) and long-term health outcomes (moderate or severe neurodevelopment disability and
respiratory morbidity) measured at 2 years corrected age.
Trial registration: ISRCTN84264977. Date assigned: 15/09/2010.
Keywords: Newborn, Patent ductus arteriosus, PDA, Echocardiography, Preterm, Ibuprofen, Bronchopulmonary
dysplasia
Background
The Ductus Arteriosus (DA) is a vessel that allows blood
from the right ventricle to bypass the fetal lungs to the
placenta. In term babies it closes spontaneously after
birth when breathing is established and is structurally
closed after a few days. However, in a large number of
preterm babies, the vessel does not close spontaneously
resulting in a condition known as Patent Ductus Arter-
iosus (PDA). Around 7000 extremely preterm babies (<
29 weeks’ gestation) are born in the UK every year. In
40% the PDA will fail to close spontaneously, even by 4
months of age [1].
PDA is associated with a number of serious and life-
threatening short and long-term complications. Compli-
cations of prematurity such as low blood pressure
(hypotension), bleeding in the lungs (pulmonary haem-
orrhage) and brain (intraventricular haemorrhage (IVH))
present soon after birth. Other systemic complications
such as necrotising enterocolitis (NEC) and bronchopul-
monary dysplasia (BPD) present before discharge, and
long-term health problems such as neurodevelopmental
disability and chronic respiratory problems can be asso-
ciated with PDA. The persistence of PDA has also been
reported to be associated with an 8-fold increase in neo-
natal mortality [2, 3]. Additionally, it places a significant
financial burden on the National Health Service (NHS).
Historically, clinicians who have been concerned about
the symptomatic PDA or complications of prematurity
have attempted to close PDA utilising medical (pharma-
cological) or surgical treatment. Traditionally, medical
treatment is instituted as prophylactic treatment (within
24 h of birth); early symptomatic treatment (usually 3–7
days after birth) and late symptomatic treatment (after
one week of age). Prophylactic pharmacological treat-
ment of all preterm babies unnecessarily exposes a large
proportion of them to the potentially serious side effects
of drug treatment, when their PDA would have closed
spontaneously. Symptomatic treatment on the contrary
delays treatment while waiting for symptoms to appear
and could result in a loss of treatment benefit as damage
may have already been done.
Moreover, the practice of a conservative approach of
not treating, seems to originate from uncertainty regard-
ing the management of PDA rather than evidence
favouring no intervention. This is because most studies
conducted to date have involved more mature preterm
babies (over 1000 g or 28 weeks’ gestation) whose PDA
is more likely to close spontaneously. In addition, the
studies were largely designed to assess PDA closure rates
rather than assessing clinically important outcomes.
It is now suggested that large PDA on echocardiog-
raphy in first 72 h (those with a diameter of ≥1.5 mm)
through which blood flow is pulsatile and unrestricted
are less likely to close spontaneously. Targeted early
treatment of a large PDA whilst asymptomatic has
the potential to overcome the disadvantages of both
the prophylactic and symptomatic approaches. Al-
though clinical detection of PDA whilst asymptomatic
is challenging, it can be assessed using bedside
echocardiography.
Non-steroidal anti-inflammatory drugs, especially
indomethacin and ibuprofen have been widely used for
the treatment of PDA. Short term efficacy of indometh-
acin and ibuprofen are equivalent in the treatment of
PDA [4]. Ibuprofen however appears to reduce the risk
of NEC and is associated with fewer clinical gastrointes-
tinal and renal side effects compared to indomethacin;
hence it is the drug of choice for this trial. Paracetamol
has also been recently reported in case studies for clos-
ure of symptomatic PDA but further research needs to
be done to establish its safety & effectiveness for early
treatment of PDA [5].
The current literature falls short of providing substan-
tive evidence on the management of PDA among ex-
treme preterm babies leading to uncertainty and
heterogeneity in clinical practices.
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A recent cohort study reported the presence of a large
PDA (defined as a PDA dimension of ≥1.5 mm) on day 3
in babies born before 28 weeks’ gestation was associated
with a threefold increase in odds of death or severe mor-
bidity compared with neonates without PDA (Odds Ra-
tio (OR) 3.4; 95% Confidence Interval (CI) 1.1 to 11.0).
Neonates with a large PDA were also reported to have
increased odds of IVH (OR 4.2; 95% CI 1.3 to 14.0) and
BPD (OR 3.7; 95% CI 1.0 to 14.0) compared with neo-
nates with no PDA [6]. In preclinical trials, pharmaco-
logic PDA closure is reported to improve alveolarisation
and minimise the impaired postnatal alveolar develop-
ment that is the pathologic hallmark of “new broncho-
pulmonary dysplasia (BPD)” [7]. An early selective
treatment approach for closure of a PDA is suggested to
trial its effect on BPD and mortality, which is the hy-
pothesis of this trial.
We aim to determine if the selective treatment of
echocardiographically confirmed large PDA in ex-
tremely preterm babies with ibuprofen within 72 h of
birth reduces the incidence of death by 36 weeks




This is a multicentre, masked, randomised, placebo-
controlled parallel group trial to determine if the select-
ive treatment of a large PDA with ibuprofen within 72 h
of birth in extremely preterm babies (23+ 0–28+ 6 weeks’
gestation) reduces the incidence of death by 36 weeks
postmenstrual age or moderate to severe bronchopul-
monary dysplasia (BPD) at 36 weeks postmenstrual age.
In addition, it assesses other secondary outcomes and
health outcomes at 2 years corrected age including sur-
vival without moderate or severe neurodevelopmental
disability and survival without respiratory morbidity.
An economic evaluation will be carried out from the
perspective of the health service. It will take the form of
a cost-effectiveness analysis presented in terms of cost
per major outcome averted. The incremental cost esti-
mate for statistically significant differences in the pre-
specified outcomes in primary and subgroup analyses
would be computed.
Data are collected from hospital records and recorded
on trial-specific case report forms (CRFs).
The main trial was preceded by an internal pilot phase
which was used to assess the suitability of trial proce-
dures and likelihood of recruitment targets being
achieved. The Trial Steering Committee (TSC) reviewed
pilot data and made recommendations regarding con-
tinuation. Data collected from the internal pilot phase of
the trial will be included in the final analysis. The entire
trial aims to recruit a total of 730 extremely preterm
babies.
All enrolled babies are followed up at 2 years of age
corrected for prematurity. Further longer-term follow-up
at primary school age may be considered but will require
separate funding. This may be undertaken as an amend-
ment to this trial or as a separate application depending
on the circumstances at the time.
The design of the trial is summarised in Fig. 1.
Setting & participants
The trial is recruiting in 32 neonatal units. Only units
that were in equipoise for the treatment of PDA, and
agreed to perform echocardiograms within 72 h of birth
to confirm the presence of a large PDA were selected.
Inclusion criteria
 Born at 23+ 0–28+ 6 weeks’ gestation
 Less than 72 h old
 Confirmed by echocardiography to have a large
PDA which
– is at least 1.5 mm in diameter (determined by
gain optimised colour Doppler),
And
– has unrestrictive pulsatile (left to right) flow
(ratio of flow velocity in PDA Maximum (Vmax)
to Minimum (Vmin) > 2:1)) or, growing flow
pattern (< 30% right to left), and no clinical
concerns of pulmonary hypertension
In addition:
 The responsible clinician is uncertain about whether
the baby might benefit from treatment to close the
PDA
 Written informed consent is obtained from the
parent(s).
Exclusion criteria
Babies will be excluded from participation in the trial if
they have:
 No realistic prospect of survival
 Severe congenital anomaly
 Clinical or echocardiography suspicion of congenital
structural heart disease that contraindicates
treatment with ibuprofen
 Other conditions that would contraindicate the use
of ibuprofen (active bleeding especially intracranial
or gastrointestinal bleeding, coagulopathy,
thrombocytopenia (platelet count < 50,000), renal
failure, life threatening infection, pulmonary
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Fig. 1 Baby-OSCAR Participant Flow Diagram
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hypertension, known or suspected necrotising
enterocolitis (NEC))
 Indomethacin, ibuprofen, or paracetamol
administration after birth
















































1Screening assessments to be completed sufficiently in advance to enable
randomisation and dosing within 72 hours of birth. If consent cannot be
obtained before echocardiographic evaluation for eligibility, echocardiographic
assessment should continue, and consent obtained when possible if a baby is
deemed eligible.
2Randomisation to be completed sufficiently in advance to enable starting IMP
dosing within 72 h of birth.
3Initial trial drug administrations to be given soon after randomisation, after 6
hours of age and within 72 hours of birth. Subsequent doses to be
administered 24 hours after the initial dose.
4Only adverse events which are serious will be recorded from first dose until 7
days after trial medication. Only unforeseeable SAEs will be reported.
5Concomitant medications to be recorded only in relation to unforeseeable
SAEs. In the event of an unforeseeable SAE all concomitant medication,
including medication given to the baby’s mother, 7 days prior to the onset of
the event to the time of its resolution must be recorded on the SAE form.
6Gross motor, cognitive, visual and hearing function will be assessed using the
PARCA-R questionnaire, expanded to include questions to assess visual and
hearing function.
7Respiratory assessments will be performed using a separate validated
questionnaire. There will be no requirement for the infants to be assessed for
respiratory and/or other neurodevelopmental functions by medically qualified
personnel.
8An echocardiogram scan will be performed when the baby reaches around 3
weeks of age (range of 18–24 days) or at hospital discharge if discharged
earlier.
9Demography and medications at 2 years will be assessed through the PARCA-
R and other questionnaires.
10If a baby transfers from the recruiting site to a continuing care site for on-
going care details of any scan would be helpful.
Primary outcome
The primary outcome is defined as a composite
outcome of incidence of death by 36 weeks
postmenstrual age, or moderate or severe BPD at 36
weeks postmenstrual age shown in Table 1.
The need for oxygen is subjective and hence oxygen
dependency is confirmed using an ‘oxygen reduction
test’. This is based on the threshold at which the baby is
able to maintain oxygen saturations ≥91% whilst
breathing in air or at a given minimum FiO2. Babies
unable to achieve this are considered to be oxygen
dependent. This test only applies to those babies whose
oxygen requirements are < 0.3, or low flow oxygen < 1.1
L/min, and who have not received any additional
respiratory support in the previous 24 h. Babies outside
of this are not tested, but data on their oxygen
requirements will be collected.
Secondary outcomes
Short term outcomes
 Death by 36 weeks postmenstrual age
 Moderate or severe BPD at 36 weeks postmenstrual
age
 Severity of BPD at 36 weeks postmenstrual age (see
table in Section 6.5)
Incidence or duration of the following up to discharge:
 Severe intraventricular haemorrhage (IVH) (grade
III/IV with ventricular dilatation or
intraparenchymal abnormality)
 Cystic periventricular leukomalacia (PVL)
 Non-cystic PVL
 Hydrocephalus
 Babies treated for retinopathy of prematurity (ROP)
 Significant pulmonary haemorrhage (fresh blood in
endotracheal tube with increase in respiratory
support)
 Treated for pulmonary hypertension with
pulmonary vasodilator
 NEC definitive and/or complicated (Bell stage II and
above) confirmed by radiology and/or
histopathology
 NEC requiring surgery
 Gastrointestinal bleeding (leading to investigation or
clinical treatment) within 7 days of the first dose of
trial drug administration
 Spontaneous intestinal perforation
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 Closed or non-significant PDA (< 1.5 mm) at around
3 weeks of age (range of 18–24 days), confirmed by
ECHO
 PDA ≥ 1.5 mm at around 3 weeks of age (range of
18–24 days)
 Medical open-label treatment of a symptomatic
PDA with a COX inhibitor
 Open-label treatment of a symptomatic PDA by
surgical treatment
 Administration and duration of inotropic support
 Total duration of respiratory support
a) Invasive ventilation through an endotracheal
tube
b) Non-invasive support through nasal CPAP, nasal
ventilation, humidified high flow nasal cannula
therapy, or low flow oxygen ≥1.1 L/min
 Discharge home on oxygen
 Duration of initial hospitalisation (birth to discharge
home)
 Postnatal steroid use for chronic lung disease
 Tolerance of ibuprofen treatment within the
foreseeable SAE reporting range, described in the
protocol, section 9.1.4
 Weight gain: a change in z score between birth and
discharge (or death if sooner)
 Head circumference: a change in head size z score
between randomisation and discharge (or death if
sooner)
Long term outcomes assessed at 2 years of age corrected
for prematurity
 Survival without moderate or severe
neurodevelopmental disability (main long-term
outcome)
 Survival
 Individual components of survival without moderate
or severe neurodevelopmental disability (in the four
domains of motor, cognitive, hearing and visual
function). Cognitive disability will be assessed by
determining the standardised non-verbal cognitive
subscale and language subscale scores obtained
through the Parent Report of Cognitive Abilities–
Revised (PARCA-R) [8] assessment. The PARCA-R
assessment will be adapted to include questions to
assess gross motor, hearing and visual function.
 Survival without respiratory morbidity. Respiratory
morbidity will be assessed by the need for oxygen or
respiratory support; presence of persistent cough
and/or wheeze; need for regular treatment for
respiratory illness; unscheduled attendances at
hospital/GP; readmission to hospital for respiratory
problems
 Duration of oxygen supplementation from
randomisation
A cost-effectiveness analysis will be conducted of
deaths and BPD events avoided and national health ser-
vices used up to 2 years of age corrected for prematurity.
Process outcomes
 Number of doses of trial medication received
 Adherence to protocol (e.g. protocol violations,




Extremely preterm babies potentially suitable for the
trial are identified by the healthcare team within the
neonatal unit. Information about the trial may be
provided antenatally or soon after birth. Parent(s) are
approached for consent after birth followed by
echocardiographic evaluation for eligibility. However, if
consent cannot be obtained echocardiographic
assessment should continue and consent obtained when
possible if a baby is deemed eligible.
The initial echocardiogram and Doppler assessment
will incorporate:
 Size of the PDA and flow pattern according to
standard trial methodology
Table 1 Severity-Based Diagnostic Criteria for BPD
Time point of
assessment:
36 weeks postmenstrual age
Therapy with oxygen > 21% and/or respiratory support for ≥ 28 days and the following:
Mild BPD; Baby is breathing room air
Moderate BPD; Baby is in 22–29% oxygen, or 0.01–1.0 L/min
Severe BPD; FiO2 ≥ 0.3, or low flow oxygen ≥ 1.1 L/min, or the baby is receiving any respiratory support (ventilation, CPAP, or high flow
oxygen therapy) to achieve saturations of ≥ 91%
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 Size of the PDA will be determined at the site of
maximum constriction (minimum diameter) using
gain optimisation typically at the pulmonary end by
determining the average of 3 separate clips
 If the size of the PDA is at least 1.5 mm, flow
pattern will be determined by placing the pulse gate
in the PDA while adjusting the velocity scale to its
highest setting. If the shunt direction is > 1/3
duration of a cycle being right to left, then a rescan
will be attempted after a few hours.
If the echocardiogram findings raise concerns about
possibility or diagnosis of congenital heart disease, a
referral will be made to a paediatric cardiologist as per
clinician discretion.
Echocardiograms
Echocardiograms are performed as part of the normal
care of preterm babies. However, clinicians are required
to perform an echocardiogram within 72 h of birth, at
around 3 weeks of age (range of 18–24 days) or at
discharge from the neonatal unit if discharged before
this time.
A proportion of echocardiogram scans will be
reviewed by a qualified clinician, who is not involved in
recruiting for the trial, to assess consistency between
clinicians.
Randomisation and blinding
Treatment allocation of ibuprofen or placebo are in a
ratio of 1:1 and blinded such that the allocation will not
be known to clinicians, the baby’s family or the trial
outcome assessors.
The randomisation system is hosted by the NPEU
Clinical Trials Unit. It is accessed by sites via a secure
password protected system. If there are problems with
accessing the system outside of normal working hours a
24 h emergency call service is available. The
randomisation program uses a minimisation algorithm
to ensure balance between the groups. These are
allocated with respect to the size of the PDA, gestational
age at birth, age at randomisation, sex, trial site, multiple
births, mode of respiratory support at randomisation (1)
invasive ventilation (by an endotracheal tube); or (2)
non-invasive respiratory support through nasal CPAP,
nasal ventilation, humidified high flow nasal cannula
therapy, or low flow oxygen ≥1.1 L/min; or (3) receiving
no mechanical ventilation, or pressure support (in room
air, or low flow oxygen < 1.1 L/min, or ambient oxygen)
and whether baby is receiving inotropes at the time of
randomisation. Babies of multiple births are randomised
individually.
If necessary, the treatment allocation code may be
broken for a participant at the request of the site PI or
clinician in charge of the baby.
Description of intervention
Ibuprofen is supplied as a clear sterile solution at a
concentration of 5 mg/ml in ampoules. Cartons contain
four 2 ml single use ampoules. Each carton is labelled
with a unique code and in compliance with the guidance
given in Annexe 13 of the European Commission’s
guidelines for Good Manufacturing Practice.
An initial loading dose of 10 mg/kg (2 ml/kg) of
ibuprofen is administered, followed by two 5mg/kg (1
ml/kg) doses at 24 and 48 h after the initial dose. Doses
are calculated on the birth weight of the baby and
preferably administered undiluted. If required, the IMP
can be diluted to appropriate volume with 5% glucose or
0.9% Sodium Chloride. Each dose should be given as a
short intravenous infusion over 15 min. All 3 doses
should be given unless there are adverse effects
necessitating stoppage. Placebo is supplied as a clear
sterile solution of 0.9% Sodium Chloride for injection.
Cartons are identical to those for ibuprofen. Volume of
placebo withdrawn from the ampoule is calculated
following the calculations for ibuprofen dosing.
Following randomisation, first dose should be
administered soon after randomisation, after 6 h of age
and within 72 h of birth. Detailed accountability records
are maintained to document which pack of medication
is allocated to which baby.
Discontinuation of intervention and withdrawal
At all stages of the trial it is made clear to the parent(s)
that they remain free to withdraw their baby without the
need to provide reason or explanation. If parent(s)
choose to withdraw their baby from trial participation,
permission will be sought to complete data collection
and use data up to the point of withdrawal.
A baby may also be withdrawn from the trial, if
deemed by the Principal Investigator to be in their best
interests.
Safety reporting
An independent DMC has been established to review
the study data and outcomes including safety reports of
Serious Adverse Events (SAEs). The DMC will ensure
the safety and wellbeing of the trial participants and
make recommendations to the Trial Steering Committee
(TSC) regarding continuance of the study or
modification of the protocol. The TSC has ultimate
responsibility for deciding whether the trial should be
stopped on safety grounds.
Relationship of each adverse event to the trial
medication is determined by a medically qualified
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individual. Causality of adverse events reported in the
preterm newborn is difficult to assess since they may be
related to the haemodynamic consequences of the
patent ductus arteriosus as well as to direct effects of
ibuprofen. In addition to this, high incidences of adverse
events are foreseeable due to the nature of the patient
population and the routine care/treatment.
Consequently, only those adverse events identified as
serious and not foreseeable will be recorded under trial
safety reporting procedures. Safety reporting for each
participant is monitored from first dose until 7 days after
trial medication. Unforeseeable SAEs are reported to the
NPEU CTU within 24 h of staff at site becoming aware
of the event. SUSARs are reported to the MHRA and
the approving Research Ethics Committee (REC) within
7 days, if the event results in death or is life-threatening,
and within 15 days for all other SUSARs. In addition, a
copy of the SAE form corresponding to the event is for-
warded to the Chair of the DMC.
All foreseeable SAEs in the trial population that do
not require reporting are specified in the full Protocol
available to all sites (Additional file 1).
Definition of end of study
The end of the trial is defined as the date when the trial
database is locked. An end of trial declaration will be
made to the MHRA and REC. Guidelines for early
cessation of the trial have been agreed with the DMC
and documented in the DMC Charter.
Data collection
The outcome data for this trial are routinely recorded
clinical items obtained from the clinical notes. No
additional blood or tissue samples are required for this
trial. All data is collected using trial specific CRFs.
Outcome data is collected until discharge home and at
2 years corrected age.
Project Management
The trial is sponsored by the University of Oxford and is
run by the NPEU CTU, based at the University of
Oxford and the Chief Investigator. On a day-to day
basis, the trial is supervised by a Project Management
Group (PMG) according to NPEU CTU SOPs and is
subject to audit and inspection. The core PMG meets
every month, either remotely or face-to-face. An ex-
tended PMG (Co-Investigator Group) meets regularly to
troubleshoot, review progress and forward plan. The
PMG reports to the TSC.
The trial is overseen by the TSC which has ultimate
responsibility for considering and, as appropriate, acting
on the recommendations of the DMC. The TSC
includes an independent chair, at least one clinician,
statistician and Patient and Public Involvement (PPI)
representative, and the Chief Investigator. The TSC
meets annually to review the progress of the trial.
The DMC is independent of the study and the TSC.
The DMC reviews the progress of the trial and interim
analysis at least annually and makes recommendations
on the conduct of the trial to the TSC.
Patient and public involvement
Patient and public representatives have been extensively
involved in trial planning, grant/protocol writing, and
preparing study materials. Advice from two PPI co-
applicants included aspects of protocol design, wording
in parent-facing documentation, as well as ongoing re-
cruitment initiatives. Contributions on documentation
were also received from Bliss baby charity [9]. A lay per-
son is a member of the TSC and is involved in trial over-
sight and dissemination of findings.
Statistics and analysis
Sample size and power calculation
Evidence from the TIPP trial suggests that the risk of
death or BPD in extremely low birth weight babies at 36
weeks postmenstrual age allocated placebo is 52% (95%
CI 48 to 56%) [10, 11]. However, this trial investigated
the effect of prophylactic treatment and included all
babies weighing 500 − 999 g. More recent information
using data derived from the latest report of Neonatal
Survey Database from the Trent region [12] provides an
approximate rate of death by or BPD at 36 weeks
postmenstrual age of 53% for all babies admitted to the
neonatal unit. These babies would have been treated
according to clinical judgement and therefore a
proportion of them would have been treated with
ibuprofen. Given that the risk of death or BPD in babies
with an echocardiographically confirmed large PDA is
inherently higher, it is estimated that the risk in this
group is 60%.
Su et al. (2008) [3] compared ibuprofen to
indomethacin in babies ≤28 weeks’ gestation having a
PDA who were less than 24 h old. The combined
outcome of death within 30 days or BPD at 36 weeks
postmenstrual age was observed to be 42% (95% CI 29
to 55%).
It is therefore expected, given that babies will be
enrolled up to 72 h after birth, that the treatment group
incidence of death/BPD at 36 weeks postmenstrual age
will be approximately 48% in the intervention arm. This
would imply an absolute risk reduction of 12% (60 to
48%) in the primary outcome of the trial for babies
randomised to treatment compared to placebo, which is
considered a clinically important difference.
Some babies will require open-label treatment (OLT)
in either the treatment or placebo arm. As open-label
treatment should be limited to symptomatic babies
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meeting only defined criteria, it is considered to have
minimal or no effect on the primary outcome. Thus, ad-
justment of the sample size for open-label treatment is
not considered necessary. A full list of OLT criteria are
specified in the full Protocol available to all sites.
Regarding outcomes at 2 years corrected age, assuming
the risk of a child dying before two years of age is 10%,
questionnaires will be sent out to around 660 parents of
surviving children. Assuming an attrition rate of 20%
reduces the sample size to around 530. The proportion
of infants surviving to 2 years without moderate or
severe neurodevelopmental disability in the control
group is expected to be 55% [13]. With outcome data
available on a total sample size of around 600 (including
deaths) the trial will have an 80% power to detect an
increase in survival without moderate or severe
neurodevelopmental disability of 11% from 55 to 66%
and 90% to detect an increase of 13% from 55 to 68%.
Description of statistical methods
Babies will be analysed in the groups to which they are
randomly assigned, comparing the outcome of all babies
allocated to ibuprofen with all those allocated to
placebo, regardless of deviation from the protocol or
treatment received (referred to as the Intention to Treat
(ITT) population).
Baseline characteristics and outcomes will be
summarised with counts and percentages for categorical
variables, means and standard deviations for normally
distributed continuous variables, or median and
interquartile range for other non-normally distributed
continuous or time-to-event variables.
For binary outcomes, risk ratios and confidence
intervals will be calculated using log binomial regression,
or if a model fails to converge a Poisson regression
model with a robust variance estimator will be used.
Continuous outcomes will be analysed using linear
regression models, with mean differences and
confidence intervals presented for approximately
normally distributed outcomes. Skewed continuous
outcomes will be analysed using quantile regression
models, with median differences and confidence
intervals presented. Time-to-event outcomes will be ana-
lysed using Cox regression and hazard ratios with confi-
dence intervals will be presented.
Analyses will be adjusted for all minimisation factors
and the correlation between siblings from multiple
births where possible. Both crude and adjusted effect
estimates will be presented, but the primary inference
will be based on the adjusted estimates.
Due to the multiple number of short-term outcomes,
and correlation between some outcomes, statistical infer-
ence will be restricted to a predefined list of tested out-
comes. Summary data by trial arm will be provided for
all other outcomes, but statistical tests (or the calcula-
tion of confidence intervals) will not be performed.
Full details of the statistical analysis will be
documented in the Statistical Analysis Plan.
Discussion
Permitted and non-permitted medications
All prescribed medications deemed necessary to provide
adequate supportive care to the baby, are permitted at
any stage during the trial period. However, open
treatment with indomethacin or ibuprofen or other non-
steroidal anti-inflammatory drugs (NSAIDs) should be
avoided unless the criteria for open-label treatment are
met.
The concomitant administration of other medication
is not restricted but should be closely monitored for an
interaction by the treating clinician.
Open-label treatment
If the clinical condition of a baby warrants intervention,
open-label treatment can be given to close the PDA
(medical or surgical). The following criteria, however,
have been devised to limit and rationalise the use of
open-label treatment but it is recognised that clinicians
may need to override this guidance in the best interests
of the baby. Clinical responsibility for the care of the
baby will remain fully with the neonatal clinical team ir-
respective of the trial.
To consider open label (Rescue) treatment, both
clinical AND echocardiographic criteria as described
below should be met:
1. Clinical findings of inability to wean on ventilator
(ventilated for at least 7 days continuously) AND
inability to wean oxygen
OR
Persistent hypotension and/or pulmonary haemorrhage
and/or signs of cardiac failure
2. Echocardiographic findings of a large PDA (PDA ≥
2.0 mm with pulsatile flow)
AND
Hyperdynamic circulation and/or ductal steal (please
refer to Baby-OSCAR ECHO workbook).
Participant confidentiality and retention of personal data
Contact details of the baby’s parent(s), as well as the
baby’s name and any other identifying details is collected
via CRFs. Parents of babies participating in the trial are
informed of and provide consent to this.
Overall responsibility for ensuring that each
participant’s information is kept confidential lies with
the Sponsor. All paper documents are stored securely
and kept in strict confidence in compliance with current
data regulations. Data collected on the CRFs are stored
in an electronic database held by the Trial Coordinating
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Centre in which the participant is identified only by a
trial specific number.
Personal data are needed to contact parents when
their children are 2 years of age, to co-ordinate follow
up, and to disseminate the results of the trial to par-
ent(s). Personal data is held securely and will not be
used for any other purpose.
Following trial completion and report publication, data
will be archived in a secure physical and electronic
location with restricted access.
Participant remuneration
A £15 voucher is sent to parents as an incentive to
complete the 2-year follow-up questionnaire; however its
completion is not dependent on receiving the voucher.
Dissemination
The success of the trial depends on a large number of
neonatal nurses, neonatologists, and parent(s). Credit for
the trial findings will be given to all who have
collaborated and participated in the trial including all
local co-ordinators and collaborators, members of the
trial committees, the Baby-OSCAR Co-ordinating
Centre and trial staff. Authorship at the head of the pri-
mary results paper will take the form “[name], [name]
and [name] on behalf of the ‘The Baby-OSCAR Collab-
orative Group’”. All contributors to the trial will be listed
at the end of the main paper, with their contribution
identified.
It is the intention of the Baby-OSCAR Collaborative
Group to present data at national/international confer-
ences, and three open-access peer-reviewed articles in-
cluding the analysis of key outcomes. The NPEU
Clinical Trials Unit will disseminate the results at con-
ferences and coordinate press releases, website promo-
tion, social and other media interest. Parents will be sent
a summary of trial publications if they wish.
Supplementary Information






AE: Adverse Event; AR: Adverse Reaction; BPD: Bronchopulmonary Dysplasia;
CI: Confidence Interval; COX: Cyclo-oxygenase; CPAP: Continuous Positive
Airway Pressure; DA: Ductus Arteriosus; DMC: Data Monitoring Committee;
ECHO: Echocardiography; GP: General Practitioner; HRA: Health Research
Authority; HTA: Health Technology Assessment; ICF: Informed Consent Form;
ICH: International Conference on Harmonisation; IMP: Investigational
Medicinal Product; IRAS: Integrated Research Application System;
ITT: Intention to Treat; IVH: Intraventricular Haemorrhage; MHRA: Medicines
and Healthcare products Regulatory Agency; NEC: Necrotising Enterocolitis;
NHS: National Health Service; NIHR: National Institute for Health Research;
NPEU CTU: National Perinatal Epidemiology Unit Clinical Trials Unit; NSAI
D: Non-Steroidal Anti-inflammatory Drug; OR: Odds Ratio; PARCA-R: Parent
Report of Cognitive Abilities–Revised; PDA: Patent Ductus Arteriosus;
PIL: Parent Information Leaflet; PMA: Postmenstrual Age; PMG: Project
Management Group; PVL: Cystic Periventricular Leukomalacia; REC: Research
Ethics Committee; RDS: Respiratory Distress Syndrome; ROP: Retinopathy of
Prematurity; SAE: Serious Adverse Event; SAR: Serious Adverse Reaction;
SUSAR: Suspected Unexpected Serious Adverse Reaction; TSC: Trial Steering
Committee
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